A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-01. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
== C == Calcium channel A type of ion channel located on the cell membrane that allows the selective entry of calcium ions (Ca²⁺) into the neuron, playing a crucial role in neurotransmitter release, gene expression, and synaptic plasticity. Capsaicin A compound found in chili peppers that activates TRPV1 receptors on sensory neurons, leading to the sensation of heat or burning. It is used in research and in topical analgesics for chronic pain. Caudate nucleus A C-shaped structure located in the basal ganglia, involved in motor control, learning, memory, and reward processing. It works closely with the putamen and globus pallidus. Central nervous system (CNS) Consists of the brain and spinal cord, responsible for processing and coordinating sensory data and motor commands. Cerebellum A brain structure located at the back of the skull that plays a central role in motor coordination, balance, posture, and some cognitive functions such as attention and language. Cerebral cortex The outermost layer of the cerebrum, composed of gray matter. It is involved in higher-order brain functions such as sensory perception, language, decision-making, and voluntary motor control. Cerebral hemisphere One of the two halves of the cerebrum, divided into left and right hemispheres. Each hemisphere specializes in different functions but communicates via the corpus callosum. Cerebrospinal fluid (CSF) A clear fluid found in the brain and spinal cord that cushions neural tissue, removes waste, and provides nutrients. It circulates through the ventricular system and subarachnoid space.
In May 1972, President Richard M. Nixon and Soviet Premier Leonid Brezhnev negotiated an easing of relations known as détente, creating a temporary "thaw" in the Cold War. The two nations planned a joint mission to dock the last US Apollo craft with a Soyuz, known as the Apollo-Soyuz Test Project (ASTP). To prepare, the US designed a docking module for the Apollo that was compatible with the Soviet docking system, which allowed any of their craft to dock with any other (e.g. Soyuz-to-Soyuz as well as Soyuz-to-Salyut). The module was also necessary as an airlock to allow the men to visit each other's craft, which had incompatible cabin atmospheres. The USSR used the Soyuz 16 mission in December 1974 to test modifications of the Soyuz atmosphere and the docking adapter to prepare for ASTP. The joint mission began when Soyuz 19 was first launched on July 15, 1975, at 12:20 UTC, and the Apollo craft was launched with the docking module six and a half hours later. The two craft rendezvoused and docked on July 17 at 16:19 UTC. The three astronauts conducted joint experiments with the two cosmonauts, and the crew shook hands, exchanged gifts, and visited each other's craft.
While Tl+ is stabilised by the inert-pair effect, this inert pair of 6s electrons is still able to participate chemically, so that these electrons are stereochemically active in aqueous solution. Additionally, the thallium halides (except TlF) are quite insoluble in water, and TlI has an unusual structure because of the presence of the stereochemically active inert pair in thallium.
British Columbia, New Brunswick: no established limits on thujone content Alberta, Ontario: 10 mg/kg Manitoba: 6–8 mg Quebec: 15 mg/kg Newfoundland and Labrador: absinthe sold in provincial liquor store outlets Nova Scotia: absinthe sold in provincial liquor store outlets Prince Edward Island: absinthe is not sold in provincial liquor store outlets, but one brand (Deep Roots) produced on the island can be procured locally. Saskatchewan: Only one brand is listed in provincial liquor stores, although an individual is permitted to import one case (usually twelve 750 ml bottles or eight one-litre bottles) of any liquor. Ontario: 3 brands of absinthe are listed for sale on the website of the Liquor Control Board of Ontario In 2007, Canada's first genuine absinthe (Taboo Absinthe) was created by Okanagan Spirits Craft Distillery in British Columbia.
== History == Before amylin deposition was associated with diabetes, already in 1901, scientists described the phenomenon of "islet hyalinization", which could be found in some cases of diabetes. A thorough study of this phenomenon was possible much later. In 1986, the isolation of an aggregate from an insulin-producing tumor was successful, a protein called IAP (Insulinoma Amyloid Peptide) was characterized, and amyloids were isolated from the pancreas of a diabetic patient, but the isolated material was not sufficient for full characterization. This was achieved only a year later by two research teams whose research was a continuation of the work from 1986.
Sources: en.wikipedia.org
The biosynthesis of tacrolimus is hybrid synthesis of both type 1 polyketide synthases (PKS 1) and nonribosomal peptide syntheses (NRPS). The research shows the hybrid synthesis consists of ten modules of type 1 polyketide synthase and one module of nonribosomal peptide synthase. The synthetic enzymes for tacrolimus are found in 19 gene clusters named fkb. The 19 genes are fkbQ, fkbN, fkbM, fkbD, fkbA, fkbP, fkbO, fkbB, fkbC, fkbL, fkbK, fkbJ, fkbI, fkbH, fkbG, allD, allR, allK and allA. There are several possible ways of biosynthesis of tacrolimus. The fundamental units for biosynthesis are following: one molecule of 4,5-dihydroxycyclohex-1-enecarboxylic acid (DHCHC) as a starter unit, four molecules of malonyl-CoA, five molecules of methylmalonyl-CoA, one molecule of allylmalonyl-CoA as elongation units. However, two molecules of malonyl-CoA are able to be replaced by two molecules of methoxymalonyl CoA. Once two malonyl-CoA molecules are replaced, post-synthase tailoring steps are no longer required where two methoxymalonyl CoA molecules are substituted. The biosynthesis of methoxymalonyl CoA to Acyl Carrier protein is proceeded by five enzymes (fkbG, fkbH, fkbI, fkbJ, and fkbK). Allylmalonyl-CoA is also able to be replaced by propionylmalonyl-CoA. The starter unit, DHCHC from the chorismic acid is formed by fkbO enzyme and loaded onto CoA-ligase domain (CoL). Then, it proceeds to NADPH dependent reduction(ER). Three enzymes, fkbA,B,C enforce processes from the loading module to the module 10, the last step of PKS 1.
== External links == GRB2+Adaptor+Protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) The Grb2 protein page on The SH2 Website GeneCards entry for Grb2 Human Protein Resource Database entry for Grb2 Archived August 13, 2006, at the Wayback Machine Grb2 information on iHOP (Information Hyperlinked over Proteins) GRB2 Info with links in the Cell Migration Gateway Archived December 11, 2014, at the Wayback Machine
== Fungi == Fungi can be used for many of the same processes as bacteria. For industrial applications, yeasts combine the bacterial advantages of being a single-celled organism that is easy to manipulate and grow with the advanced protein modifications found in eukaryotes. They can be used to produce large complex molecules for use in food, pharmaceuticals, hormones, and steroids. Yeast is important for wine production and as of 2016 two genetically modified yeasts involved in the fermentation of wine have been commercialized in the United States and Canada. One has increased malolactic fermentation efficiency, while the other prevents the production of dangerous ethyl carbamate compounds during fermentation. There have also been advances in the production of biofuel from genetically modified fungi. Fungi, being the most common pathogens of insects, make attractive biopesticides. Unlike bacteria and viruses they have the advantage of infecting the insects by contact alone, although they are out competed in efficiency by chemical pesticides. Genetic engineering can improve virulence, usually by adding more virulent proteins, increasing infection rate or enhancing spore persistence. Many of the disease carrying vectors are susceptible to entomopathogenic fungi. An attractive target for biological control are mosquitos, vectors for a range of deadly diseases, including malaria, yellow fever and dengue fever.
On the other hand, the inverse placebo effect (or "knowcebo" effect) caused by blinding failure may create an illusion of large effect sizes with psychedelics. Psilocybin has not received regulatory approval for medical use in the United States. A 2024 network meta-analysis of RCTs of therapies for treatment-resistant depression, with effectiveness measures being response and remission rates, likewise found that psilocybin was more effective than placebo and, considering both effectiveness and tolerability or safety, recommended it as a first-line therapy, along with ketamine, esketamine, and electroconvulsive therapy (ECT). However, the quality of evidence was generally rated as low or very low. Meta-analyses of psychedelics for depression and other psychiatric conditions have found that psilocybin has the greatest number of studies and the most evidence of benefit, relative to other psychedelics like ayahuasca and LSD. Preliminary meta-analyses suggest that improvements in depressive symptoms with psilocybin are dose-dependent and that higher doses may result in greater improvements than lower doses. One meta-analysis found that the highest assessed dose in clinical trials, 30 to 35 mg per 70 kg body weight, was the most effective, with an effect size (Hedges' g) of 3.1 (relative to 1.3 overall), but based on only one study for that dosing subgroup. This meta-analysis included both RCTs and prospective open-label studies, and calculated effect sizes by comparing to the placebo group or by using pre-treatment (baseline) values.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.